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Key Points  
 Targeted mutations of amino acid residues involved in FXIII-A subunit 
interactions affect FXIII-A expression and activity.  
 We have identified eight amino acid residues forming four intersubunit 
interactions that may be essential for FXIII-A2 dimer stability. 
Abstract 
Coagulation factor XIII (FXIII) is the main stabilizer of the fibrin clot. It circulates in 
plasma as a tetramer of two A and two B subunits. Under physiological conditions, 
FXIII-A exists as a dimer (FXIII-A2). The interactions between the FXIII-A subunits 
that stabilize the FXIII-A2 dimer are not fully understood. Therefore, we designed a 
systematic approach to identify amino acid residues crucial for the expression and 
stability of FXIII-A2. Based on the available FXIII-A2 crystal structure, we identified 12 
amino acid residues forming intersubunit salt bridges and 21 amino acid residues 
forming hydrogen bonds between the two A-subunits. We chose ten amino acid 
residues that form five particularly strong interactions, performed site-directed 
mutagenesis and expressed the mutants in CHO cells. Disruption of these 
interactions by single mutation of Lys257, Lys113, Asp343, Glu401, or Asp404 
abolished the expression of properly folded, soluble and functional FXIII-A in CHO 
cells. On the contrary, mutation of Glu111, Arg100, or Asn112 had no significant 
effect on FXIII-A expression. Our results suggest that four intersubunit interactions 
(Arg11-Asp343, Lys113-Asp367, Lys257-Glu401 and Arg260-Asp404) are essential 
for the stability of FXIII-A2. Our findings are supported by reported mutations at 
Lys257, Arg260, and Asp404 found in patients with congenital FXIII-A deficiency. 
Introduction 
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Coagulation factor XIII (FXIII) keeps blood clots stable by crosslinking fibrin polymers 
and protecting fibrin clots from fibrinolytic degradation. It is essential to form a 
stabilized clot during coagulation to stop bleeding. Deficiency of FXIII causes 
bleeding manifestations, including potentially life-threatening intracranial bleeding.1 
FXIII-A is a protransglutaminase in a transglutaminase (TG) family of nine proteins. 
Eight members of the family can exist as monomers, including TG1-TG7 and human 
erythrocyte membrane protein band 4.2, while FXIII-A only exists as a dimer in 
vivo.2,3 Plasma FXIII circulates in plasma as a heterotetramer (FXIII-A2B2) of two 
catalytic A-subunits (FXIII-A) and two carrier/regulatory B-subunits (FXIII-B).4 The 
catalytic A-subunit contains the transglutaminase active site (Cys314) and is the 
functional subunit of FXIII.2 The B-subunit is a carrier protein that stabilizes FXIII-A2 
in plasma.5 Cellular FXIII is a homodimer of two catalytic A-subunits (FXIII-A2) 
present in the cytoplasm of certain cells.5 No non-activated monomeric FXIII-A is 
found in vivo.2,5  
FXIII-A consists of 731 amino acids, without the initiator methionine, and has five 
structural domains: activation peptide (amino acids 1-37), β-sandwich (amino acids 
38-184), core domain (amino acids 185-515), β-barrel 1 (amino acids 516-628), and 
β-barrel 2 (amino acids 629-731). Two identical FXIII-A subunits assemble the dimer 
(FXIII-A2).
5 Because there is no covalent bond between two FXIII-A subunits, dimer 
formation is ensured by non-covalent interactions including salt bridges, hydrogen 
bonds (H-bonds), hydrophobic interactions, and van der Waals forces. The salt 
bridge is the strongest interaction among the non-covalent interactions.6,7 A salt 
bridge is the interaction between two ionized molecules (also called ion-pairs), 
defined as a bond formed by an acid and a base with close donor-acceptor pKa 
matching.8 In proteins, salt bridges occur between amino acids with opposite full-
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electron charges and are in fact a combination of two non-covalent interactions, ionic 
and hydrogen bonding. A salt bridge is generally considered to exist when the 
distance between centers of charge are less than 4 Å.9 The H-bond is another 
important interaction that maintains protein structure and protein folding. The binding 
strength of H-bonds is weaker than salt bridges, but stronger than van der Waals 
forces.6 The distance between H-bond donor and acceptor is generally considered 
between 1.6 and 2.5 Å.10 In protein-ligand complexes H-bonds were inferred when 
the distance was less than 3.5 Å.11 Compared to van der Waals forces, salt bridges 
and H-bonds are strong non-covalent interactions6 which could make important 
contributions to FXIII-A2 dimer formation.  
The dimer formation is crucial for the stability of FXIII-A2 as two previous case reports 
on patients with congenital FXIII-A deficiency showed that impaired dimer formation 
makes FXIII unstable. In these case reports, the FXIII-A Arg260Cys and Tyr283Cys 
mutations were associated with impaired dimer assembly and decreased stability of 
mutant FXIII-A2.
12,13 Our group has previously investigated the function of the 
activation peptide in stabilization of FXIII-A2. Our findings suggested that the amino 
acid sequence from Phe8 to Arg12 plays a crucial role in intersubunit interactions in 
the FXIII-A2 dimer.
14 Those mentioned studies provided useful but limited information 
about the interactions that keep FXIII-A2 stable. The FXIII 3D structure has been 
studied for many years, but the amino acid sequences or individual amino acid 
residues crucial for the integrity of the FXIII molecule, including FXIII-A2 dimer 
formation, are still not well understood.  
We have therefore undertaken a systematic approach that used in silico analysis of 
the FXIII-A2 crystal structure to identify potentially crucial amino acid residues within 
the FXIII-A2 dimer interface and to design their mutations, followed by single site-
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directed mutagenesis and cell expression studies to confirm which amino acid 
residues are vital for expression and stability of the FXIII-A protein. 
 
 
Methods 
Computer analysis methods and design of mutations 
We used the FXIII-A2 crystal structure 1F13.pdb
15 obtained from the Protein Data 
Bank in Europe (PDBe), and the PISA (Proteins, Interfaces, Structures and 
Assemblies) server (http://www.ebi.ac.uk/pdbe/pisa/) to identify the amino acid 
residues forming intersubunit salt bridges and H-bonds at the interface between two 
A-subunits. We further visualized the identified amino acid residues using Swiss-
PdbViewer16 (https://spdbv.vital-it.ch/) and evaluated salt bridges and H-bonds 
according to the distance and position between donor and acceptor atoms.  
In order to investigate the effects of the identified amino acid residues on the stability 
of FXIII-A2, we designed mutations using Swiss-PdbViewer. Principally, we changed 
the amino acid residues with charged side chains to amino acid residues without 
charge but of similar size, and this disrupted the electrostatic interactions without 
inducing significant steric changes so that the conformation should not significantly 
change after mutation. 
For Lys257, we designed two mutations, Lys257Glu and Lys257Leu. The Lys257Glu 
mutation was identified in a FXIII deficient patient17 but not further characterized in 
vitro, therefore we decided to express this mutation as well. Mutation of lysine, a 
polar amino acid with positive charge, into glutamic acid, a polar amino acid with 
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negative charge, is expected to disrupt the interaction of Lys257-Glu401 by repelling 
electric forces, which could significantly influence the conformation of FXIII-A2. 
Hence, we designed for our study another mutation, Lys257Leu. Leucine is a non-
polar amino acid that would not support salt bridge or H-bond formation with the 
opposite A-subunit. Since its structure and molecular weight (131.17 g/mol) are 
similar to lysine (146.19 g/mol), we would not expect this mutation to significantly 
alter the conformation of FXIII-A.  
For Arg100, we also designed two mutations, Arg100Gln and Arg100Leu. Arginine is 
a polar amino acid with positive charge. With the two mutations we aimed at testing 
its replacement by another polar (glutamine) and by a non-polar (leucine) amino acid. 
We applied similar considerations in the design of the following mutations: 
Glu111Leu, Asn112Val, Lys113Leu, Asp343Val, Glu401Leu, and Asp404Val. 
According to visualization in PdbViewer, we expected all these mutations to disrupt 
the salt bridge and/or H-bond interactions between the two A-subunits, without major 
conformational changes within the FXIII-A monomers. 
 
Wild-type and mutant F13A expression plasmids 
We used the pcDNA5/FRT expression plasmid containing the human wild-type F13A 
cDNA sequence (pcDNA5/FRT-WT-F13A) that we had cloned previously.14 We 
constructed the mutant F13A expression plasmids by site-directed mutagenesis of 
the wild-type expression plasmid with the GeneArt® Site-Directed Mutagenesis 
PLUS Kit (Invitrogen). We designed the mutagenic primers using the web-based 
GeneArt® Primer and Construct Design Tool 
(http://www.thermofisher.com/order/oligoDesigner). The primers are listed in Table 1. 
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We performed the mutagenesis reaction according to the manufacturer’s instruction 
using One Shot® MAX Efficiency® DH5α™-T1R competent cells (Invitrogen). We 
purified the plasmids using the PureLink™ HiPure Plasmid Midiprep Kit (Invitrogen) 
and then used the sequencing service by Microsynth (Balgach, Switzerland) with 
standard CMV-forward and BGH-reverse primers. The plasmids with correct 
sequences were chosen for transfection. 
 
Stable expression of wild-type and mutant FXIII-A proteins  
We co-transfected Flp-In™ Chinese hamster ovary (CHO) cells (Invitrogen) with the 
pOG44 plasmid encoding a specific recombinase and one of our expression plasmids 
(wild-type FXIII-A or mutant FXIII-A plasmids) using Lipofectamine™ 3000 
Transfection Reagent (Invitrogen) according the manufacturer’s protocol. We cultured 
the transfected cells with 600 μg mL-1 hygromycin (Invitrogen) for selection. After 
culture for three weeks, stable cell lines for FXIII-A expression were obtained. Cell 
lysates were prepared as described below and stored frozen until further analysis.  
 
Analysis of wild-type and mutant FXIII-A proteins  
We employed ELISA, Western blotting, and a FXIII activity assay to analyze the cell 
lysates as described previously.18 Cell lysates from untransfected cells were used as 
negative control.  
For ELISA, we lysed the cells in a non-denaturing buffer (140 mM NaCl, 10 mM 
HEPES, pH 7.4, 1% Triton X-100, containing protease inhibitor cocktail without EDTA 
(Pierce, Thermo Fisher Scientific)).  We diluted the cell lysates 1:50, 1:100 and 1:200 
in Tris-buffered saline (TBS) (140 mM NaCl, 40 mM Tris, pH 7.4) containing 0.1% 
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bovine serum albumin (BSA). The assay was performed according to the protocol 
published previously.19 The standard curve was obtained with serial dilutions of 
recombinant FXIII-A2 (Zedira, Darmstadt, Germany). We measured the total protein 
concentration of the cell lysates using Pierce™ BCA Protein Assay Kit (Thermo 
Fisher Scientific) according to the manufacturer’s protocol, and calculated the FXIII-A 
expression per 100 µg of total protein. 
For Western blotting, the cells were lysed directly in 1X SDS–Laemmli sample buffer 
(Bio-Rad, Hercules, USA) (about 200 μL/106 cells). Proteins were separated by 
electrophoresis on Bolt™ 8% Bis-Tris Plus Gels (Invitrogen) with 1X Bolt™ MES SDS 
Running Buffer (Invitrogen), and transferred onto Immun-Blot® PVDF membrane 
(Bio-Rad) with 1X Bolt™ Transfer Buffer (Invitrogen). We incubated the membrane 
for three hours at room temperature with a primary rabbit monoclonal anti-FXIII-A 
antibody (ab179444; Abcam, Cambridge, UK) diluted 1:2,000, followed by incubation 
with a horseradish peroxidase-conjugated goat anti-rabbit secondary antibody 
(31460; Thermo Fisher Scientific) diluted 1:10,000, and development with the 
WesternBright Quantum HRP chemiluminescent substrate (Advansta, Menlo Park, 
USA). Finally, we visualized the membrane with a Fusion Solo S imaging system 
(Vilber, Marne-la-Vallée, France). 
We measured FXIII transglutaminase activity of wild-type and FXIII-A mutants using 
a biotin incorporation assay as described previously.18,20 Briefly, we loaded cell 
lysates containing 12 ng of wild-type or mutant FXIII-A, diluted in TBS (40 mM Tris, 
140 mM NaCl, pH 7.4), onto the fibrinogen-coated plate and added the reaction mix 
containing thrombin, calcium, and the FXIII substrate biotinpentylamine. The 
reactions were stopped with EDTA at different time points (3, 10, 20, 30 and 40 min) 
and incorporated biotinpentylamine was detected via alkaline-phosphatase-labelled 
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streptavidine. The assay was performed in duplicates in three separate experiments, 
using two different cell lysates from two separate expression experiments. We 
calculated the initial slopes of the activity over time curves for the time intervals of 3-
10 min and 3-20 min as change of optical density per minute (∆OD/min) and 
compared the FXIII-A variants with the wild-type using a t-test (IBM© SPSS© 
Statistics, version 26.0, IBM Corporation, Armonk, New York, USA). 
 
Results 
In silico analysis of the FXIII-A2 crystal structure suggests ten amino acid 
residues that form five particularly strong interactions between two A-subunits 
In a first step, our aim was to identify in silico the amino acid residues that may be 
crucial for FXIII-A2 dimer formation. We identified 12 amino acid residues forming salt 
bridges and 21 amino acid residues forming H-bonds, among them ten are involved 
in both salt bridge and H-bond formation (Figure 1). Therefore, we supposed that 
these ten amino acid residues form the following five particularly strong interactions 
between the two A-subunits: Arg11-Asp343, Glu111-His450, Lys113-Asp367, 
Lys257-Glu401, Arg260-Asp404 (Figure 1). As an estimate of the strength21 of these 
five interactions, we measured the distance between donor and acceptor atoms as 
shown in Table 2.  
The ten amino acid residues are localized along the interface between the two A-
subunits and can be divided into three groups according to the protein domains 
involved (Figure 2). The first group maintains interactions between β-sandwich 
domain and core domain and comprises Glu111 and Lys113. Together with Asn112 
and Arg100, which are only involved in H-bond formation, these four amino acid 
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residues of the β-sandwich domain of one monomer interact with Asp447, His450, 
Asp351 and Asp367 in the core domain of the opposite monomer. The second group 
of amino acid residues maintain interactions between the two core domains of 
opposite FXIII-A monomers. This group comprises Arg260 and Lys257 which interact 
with Asp404 and Glu401, respectively, in the core domain of the opposite A-subunit. 
The third group maintains interactions between core domain and activation peptide 
and comprises Asp343 of the core domain that interacts with Arg11 and Arg12 of the 
opposite activation peptide. From this in silico analysis we concluded, that these 
three groups of amino acid residues are crucial for maintaining the interactions 
between two A-subunits.  
In a second step, we designed mutations of the amino acid residues that are 
putatively important for maintaining the FXIII-A2 dimeric structure and hence stability. 
Our aim was to disrupt the interactions by introducing single mutations that do not 
support the formation of salt bridges and/or H-bonds. At the same time we took care 
to choose amino acids of similar size in order to prevent significant conformational 
changes due to steric hindrance alone. Of the five pairs of amino acid residues 
forming the five strong interactions described above, we mutated at least one amino 
acid residue of each pair. 
 
 
Mutations of five amino acid residues abolished the expression of properly 
folded, soluble FXIII-A in CHO cells 
In the next step, the FXIII-A mutants were stably expressed in CHO cells. As shown 
by the ELISA and Western blot results in Figure 3, we were unable to detect the 
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expression of properly folded and soluble FXIII-A in case of mutations at Lys257 
(Lys257Glu and Lys257Leu), Lys113Leu, Asp343Val, Glu401Leu, and Asp404Val. 
The mutants Glu111Leu (86 % ± 8 %), Asn112Val (118 % ± 3 %), and Arg100Leu 
(97 % ± 5 %) were expressed to a similar extent as the wild-type, whereas 
Arg100Gln strongly reduced the expression to 32 % ± 7 %.  
 
FXIII activity was altered in some FXIII-A variants  
Finally, we investigated the activity of the FXIII-A variants using an incorporation 
assay. We did not find any detectable FXIII-A activity in the mutations at Lys257, 
Lys113, Asp343, Glu401, and Asp404, which is consistent with our ELISA results. 
FXIII activity over time of the wild-type and variants that were expressed to a 
measurable extent, i.e. Arg100Gln, Arg100Leu, Glu111Leu, and Asn112Val, is 
shown in Figure 4A. The initial activity rates, calculated as slope of the curves during 
the first 10 or 20 min are shown in Table 3. When we compared the initial slopes of 
the wild-type and mutants (as illustrated in Figure 4B), Arg100Gln and Arg100Leu 
variants showed a significantly reduced activity in the first 20 min compared with the 
wild-type (p<0.001). The Glu111Leu variant on the other hand showed a trend 
towards increased initial activity in the first 10 min (p=0.067).   
 
 
Discussion 
It is still not well understood how the FXIII-A2 dimer is held together. There is some 
anecdotal evidence from patients with congenital FXIII-A deficiency for mutations that 
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disrupted FXIII-A2 dimer formation. A Tyr283Cys mutation identified in a FXIII-
deficient patient was expressed in a megakaryoblastic cell line and found solely in 
monomeric form.13 An Arg260Cys mutation identified in a FXIII-deficient patient was 
proposed to preclude the ionic interaction (salt bridge) between Arg260 and Asp404 
on the opposite A-subunit.22 When this mutant was expressed in yeast, expression 
levels were significantly reduced and indeed no FXIII-A2 dimer was detected, but part 
of the unstable protein was present in monomeric form.12 An Asp404His mutation 
was detected in heterozygous form in a FXIII-deficient patient. The protein was not 
expressed but molecular modelling predicted disruption of the stabilising interaction 
with Arg260 of the opposite A-subunit.23  While the mutations mentioned above are 
all located in the core domain of the FXIII-A molecule, our group has shown 
previously that an Arg11Gln mutation in the activation peptide also abolished FXIII-A 
expression, possibly by disabling intersubunit interactions.14 We were therefore 
wondering whether there was a “hot-spot” region within the interface between the two 
A-subunits of the FXIII-A2 dimer that is of particular importance for intersubunit 
interactions, or whether rather individual amino acid residues scattered along the 
entire interface may be crucial for intersubunit interactions leading to dimer formation 
and ensuring protein stability. 
In our systematic approach reported here we identified potential candidates of 
important amino acid residues by analyzing data from the published crystal structure. 
For confirmation we expressed FXIII-A variants where we had mutated the putatively 
crucial amino acid residues. Our results suggest that four intersubunit interactions are 
crucial for expression and stability of FXIII-A: Arg11-Asp343, Lys113-Asp367, 
Lys257-Glu401 and Arg260-Asp404. These interactions involve the activation 
peptide (Arg11), the β-sandwich domain (Lys113) and the core domain (Lys257, 
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Arg260, Asp343, Asp367, Glu401, Asp404). That means that there is no “hot-spot” 
region for intersubunit interactions, but amino acid residues that significantly stabilize 
FXIII-A2 are distributed over the interface and several protein domains. The β-barrel 
domains have been attributed a role in the enzymatic activity of FXIII by protecting 
the active site cysteine,24 but do not contribute significantly to FXIII-A2 dimer 
formation. 
In our study, single mutations of Lys113, Lys257, Asp343, Glu401, and Asp404 
abolished the expression of FXIII-A. We cannot completely rule out that any 
misfolded, insoluble or inactive protein was still expressed. We suggest, however, 
that the combination of different detection methods, i.e. sandwich ELISA with two 
different polyclonal antibodies, SDS PAGE followed by Western blotting with a 
monoclonal antibody, and the functional incorporation assay, makes it less likely that 
we have missed any misfolded, insoluble or inactive protein. The lack of FXIII-A in 
patients with Lys257Glu17 and Asp404His23 mutations, as well as several mutations 
of Arg260,1 supports our findings and attributes clinical relevance to the interactions 
Lys257-Glu401 and Arg260-Asp404 that occur in close proximity to each other in the 
core domain.  
Asp343 forms a salt bridge with Arg11 in the opposite FXIII-A subunit and we have 
shown here and previously14 that mutations of either of these amino acid residues 
abolish functional FXIII-A expression. In silico analysis of the crystal structure also 
showed the possibility that Asp343 forms an ionic interaction with Arg12, with a 
distance between donor and acceptor residues of 3.29Å. However, the position of 
these two amino acid residues does not support H-bonds which contribute to strong 
salt bridges. We therefore conclude that Arg12 and Asp343 do not form a strong salt 
D
ow
nloaded from
 https://ashpublications.org/blood/article-pdf/doi/10.1182/blood.2019002127/1502857/blood.2019002127.pdf by U
N
IVER
SITATESBIBLIO
TH
EK BER
N
 user on 06 D
ecem
ber 2019
14 
 
bridge that stabilizes the FXIII-A2 dimer, which is supported by our previous finding 
that an Arg12Gln mutation had no influence on FXIII-A expression.14   
In our study, single mutations of Arg100, Glu111, and Asn112 had no deleterious 
effect on FXIII-A protein expression, only Arg100Gln (but not Arg100Leu) reduced 
the expression level. We therefore conclude that the intersubunit interactions these 
amino acids are involved in, Arg100-Asp447, Glu111-His450, and Asn112-Asp367, 
are not essential for the stability of FXIII-A2. The result for Glu111 was unexpected 
since a strong interaction of both ionic interaction and H-bond was suggested by the 
structural analysis. However, the distance between Glu111 and His450 is the longest 
distance of the five interactions we identified as potentially particularly important, and 
this could mean that Glu111-His450 may be in fact the weakest interaction among 
those five interactions. Mutations of Arg100 and Asn112 were predicted to disrupt H-
bond interactions with Asp447 and Asp367, respectively, on the opposite A-subunit. 
However, disruption of a single H-bond interaction may not be enough to prevent 
intersubunit interactions and dimer formation. Similarly, the loss of the H-bond by the 
Arg100Gln mutation was not assumed as the reason for the decreased FXIII-A 
expression we observed. Since the Arg100Leu variant was expressed normally, we 
suppose that the Arg100Gln mutation may have caused other subtle changes to the 
structure of FXIII-A. Interestingly, both Arg100 variants displayed reduced FXIII 
activity although no conformational changes caused by the mutations were predicted. 
Possible explanations include stronger subunit interactions or reduced accessibility 
for thrombin or FXIII substrates. In case of the Glu111Leu variant, we observed 
slightly increased FXIII activity compared with the wild-type in the early time interval 
(3-10mins). The difference almost reached statistical significance, suggesting that 
Glu111Leu may be activated faster than wild-type FXIII-A. We hypothesize that this 
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mutation has a mild weakening effect on intersubunit interactions which may facilitate 
the dissociation during activation of FXIII-A. This may be in line with a recent study by 
Anokhin et al.25 who showed new evidence that FXIII activation may involve 
dissociation of FXIII-A2 into monomers. This would raise the question, how the 
postulated strong intersubunit interactions stabilizing the dimer would be broken 
during FXIII activation. In case of the Arg11-Asp343 interaction, proteolytic cleavage 
and subsequent release of the activation peptide26 would obviously disrupt the 
Arg11-Asp343 interaction. Analytical ultracentrifugation studies showed that thrombin 
cleavage of a single activation peptide is sufficient to weaken intersubunit 
interactions and initiate the transition from dimer to monomer.25 We can only 
speculate on the mechanisms of how the other three putatively strong and stabilizing 
interactions Lys113-Asp367, Lys257-Glu401 and Arg260-Asp404 would be broken 
during FXIII activation. In their article on structural and functional aspects of FXIII, 
Komaromi et al.2 discuss the conformational changes that occur during the FXIII 
activation process. The stretch of amino acids Met350-Lys366 is part of the hinge 
region of the core domain that allows movement of the β-barrel domains, and Asp367 
is located right next to that region. An increase in solvent accessible surface area 
upon activation has been described for the region spanning amino acids 248–264, 
indicating that this region also undergoes significant conformational changes during 
activation. These conformational changes could disrupt the interactions Lys113-
Asp367, Lys257-Glu401, and Arg260-Asp404, possibly contributing to dimer 
dissociation and transition to the monomeric form. 
In our study, we took a systematic approach to investigate amino acid residues that 
are involved in intersubunit interactions. However, we did not express variants of all 
the amino acids identified in our in silico analysis, but we focused on the putatively 
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strongest combined ionic interaction and H-bond interactions and expressed at least 
one variant of every interaction pair. In addition, as proof-of-concept, we also 
expressed some variants of amino acids involved in H-bonds only. Hydrophobic 
interactions are also important interactions for maintaining protein structures, but 
these interactions are rarely single atom interactions so we did not take those into 
account.  
A limitation of our study is that we cannot confirm that the undetectable FXIII-A 
variants would indeed exist as monomers only due to the disrupted intersubunit 
interactions, and hence we cannot confirm a causal link between the lack of 
expression of a mutant protein and the potential failure to form dimers. Failure to form 
a dimer has been reported for the Arg260Cys and Tyr283Cys mutations found in 
patients with congenital FXIII deficiency. Although small amounts sufficient to be 
analysed were expressed in vitro, those monomeric forms were unstable11,12, which 
supports our hypothesis.    
In summary, we have presented four FXIII-A intersubunit interactions, Arg11-Asp343, 
Lys113-Asp367, Lys257-Glu401 and Arg260-Asp404, that may be essential for the 
expression and stability of FXIII-A2. Our findings are supported by reported mutations 
at Lys257, Arg260, and Asp404 found in patients with congenital FXIII-A deficiency. 
Our study contributes to a better understanding of the crucial elements that hold the 
FXIII molecule together. 
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Tables 
 
Table 1. Primers for site-directed mutagenesis of the wild-type expression 
plasmid (pcDNA5/FRT-WT-F13A). The mutated codons are labeled with gray 
color and underlines. 
Mutation Sequence 5’→ 3’ 
Arg100Leu 
Forward primer: 5’- AGAAGGGATCTCTTCCTGGTGGAATACGTCAT -3’ 
Reverse primer: 5’- ATGACGTATTCCACCAGGAAGAGATCCCTTCT -3’ 
Arg100Gln 
Forward primer: 5’- AGAAGGGATCTCTTCCAGGTGGAATACGTCAT -3’ 
Reverse primer: 5’- ATGACGTATTCCACCTGGAAGAGATCCCTTCT -3’ 
Glu111Leu 
Forward primer: 5’-GGTCGCTACCCACAGCTGAACAAGGGAACCTA-3’ 
Reverse primer: 5’- TAGGTTCCCTTGTTCAGCTGTGGGTAGCGACC-3’ 
Asn112Val 
Forward primer: 5’- CGCTACCCACAGGAGGTCAAGGGAACCTACAT -3’ 
Reverse primer: 5’- ATGTAGGTTCCCTTGACCTCCTGTGGGTAGCG -3’ 
Lys113Leu 
Forward primer: 5’- TACCCACAGGAGAACCTGGGAACCTACATCCC -3’ 
Reverse primer: 5’- GGGATGTAGGTTCCCAGGTTCTCCTGTGGGTA -3’ 
Lys257Leu 
Forward primer: 5’- AGAGGGAATCCCATCCTAGTCAGCCGTGTGGG -3’ 
Reverse primer: 5’- CCCACACGGCTGACTAGGATGGGATTCCCTCT -3’ 
Lys257Glu 
Forward primer: 5’- AGAGGGAATCCCATCGAAGTCAGCCGTGTGG -3’ 
Reverse primer: 5’- CCACACGGCTGACTTCGATGGGATTCCCTCT -3’ 
Asp343Val 
Forward primer: 5’- ATTTCTCTGCCCATGTTAATGATGCCAATTT -3’ 
Reverse primer: 5’- AAATTGGCATCATTAACATGGGCAGAGAAAT -3’ 
Glu401Leu 
Forward primer: 5’- GACAGCACCCCCCAGCTAAATAGCGATGGCAT -3’ 
Reverse primer: 5’- ATGCCATCGCTATTTAGCTGGGGGGTGCTGTC -3’ 
Asp404Val 
Forward primer: 5’- CCCAGGAAAATAGCGTTGGCATGTATCGGTG -3’ 
Reverse primer: 5’- CACCGATACATGCCAACGCTATTTTCCTGGG -3’ 
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Table 2. The distance between donor and acceptor atoms of the amino acid 
residues involved in five particularly strong interactions.  
Amino acid interactions The interacting residues and atoms Distance (Å) 
Lys257-Glu401 Lys257[NZ]-Glu401[OE1] 2.56 
Arg11-Asp343 
Arg11[NH1]-Asp343[OD2] 2.58 
Arg11[NH2]-Asp343[OD1] 2.98 
Arg260-Asp404 
Arg260[NE]-Asp404[OD1] 2.71 
Arg260[NH2]-Asp404[OD2] 3.24 
Lys113-Asp367 Lys113[NZ]-Asp367 [OD1] 3.05 
Glu111-His450 Glu111[OE1]-His450[NE2] 3.26 
 
 
Table 3. Initial slopes of the activity-over-time curves. 
FXIII-A variant Slope 3-10 min, 
ΔOD/min 
p-value 
Slope 3-20 min, 
ΔOD/min 
p-value 
Wild-type 0.0403 (0.0116) - 0.0443 (0.0051) - 
Arg100Gln 0.0291 (0.0239) n.s. 0.0207 (0.0049) < 0.001 
Arg100Leu 0.0249 (0.0224) n.s. 0.0213 (0.0034) < 0.001 
Glu111Leu 0.0585 (0.0124) 0.067 0.0457 (0.0073) n.s. 
Asn112Val 0.0343 (0.0418) n.s. 0.0427 (0.0081) n.s. 
Data are shown as mean (SD). The p-value describes the comparison with the wild-
type tested by t-test. n.s. = not significant 
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Figure Legends 
Figure 1. Amino acid residues of the FXIII-A2 intersubunit interface involved in 
intersubunit interactions. Amino acid residues of the FXIII-A monomer shown as 
yellow ribbon are depicted against the grey space-filled model of the opposite FXIII-A 
monomer. Ten amino acid residues are involved in salt bridge and H-bond formation 
and suggested to form five particularly strong interactions (highlighted in the orange 
box) between the two A-subunits. 
 
Figure 2. Detailed location of amino acid residues involved in intersubunit 
interactions. The amino acid residues can be grouped according to their protein 
domain and mediate interactions (indicated as dashed green lines) between the β-
sandwich and core domain, between core domain and core domain, and between the 
activation peptide and core domain. The protein backbone of the first A-subunit is 
shown as grey ribbon, the backbone of the second A-subunit is shown as orange 
ribbon. The underlined amino acid residues were mutated to disrupt the interactions. 
The five amino acid pairs assumed to form particularly strong interactions are written 
in bold italic font.  
 
Figure 3. Protein expression of FXIII-A variants. (A) ELISA results showing the 
expression of the FXIII-A variants relative to the wild-type FXIII-A. Data are shown as 
mean from three experiments with error bars representing standard deviation. (B) 
Western blot showing the FXIII-A variants detected with a monoclonal anti-FXIII-A 
antibody. Controls include a molecular weight marker (MW), lysate from 
untransfected CHO cells (UT) as negative control, lysate from CHO cells transfected 
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with wild-type FXIII-A (WT), and commercially available rFXIII-A (Zedira) as positive 
control (20 ng and 50 ng loaded). 
 
Figure 4. FXIII activity measured with an incorporation assay. Upon FXIII 
activation with thrombin and Ca2+, transglutaminase activity was measured for up to 
40 min. (A) FXIII activity of the wild-type and variants that were expressed to a 
measurable extent, i.e. Arg100Gln, Arg100Leu, Glu111Leu, and Asn112Val, is 
shown as absorbance over time (mean OD values ± standard deviation). The values 
are from three separate experiments. (B) The slopes of the activity curves during the 
first 10 min (dark grey bars) and 20 min (light grey bars) were calculated as ∆OD/min. 
Data are depicted as mean ± standard deviation. The asterix indicates statistical 
significance (p<0.001).  
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